Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT00002854
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- German Hodgkin's Lymphoma Study Group
- Target Recruit Count
- 220
- Registration Number
- NCT00025636
- Locations
- 🇧🇪
Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium
🇩🇪Universitaetsklinikum Essen, Essen, Germany
🇩🇪Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet, Greifswald, Germany
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 79
- Registration Number
- NCT00020943
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 9
- Registration Number
- NCT00045617
- Locations
- 🇺🇸
CCOP - Columbus, Columbus, Ohio, United States
🇺🇸Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Scotland and Newcastle Lymphoma Group
- Registration Number
- NCT00003815
- Locations
- 🇬🇧
Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00003273
- Locations
- 🇺🇸
Cancer Research Center of Hawaii, Honolulu, Hawaii, United States
🇺🇸State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States
🇺🇸Maine Children's Cancer Program, Scarborough, Maine, United States
Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 104
- Registration Number
- NCT00047320
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 14
- Registration Number
- NCT00025272
- Locations
- 🇺🇸
CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States
🇺🇸Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 118
- Registration Number
- NCT00003631
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: imatinib mesylateDrug: methotrexateDrug: vincristine sulfateDrug: leucovorin calciumProcedure: peripheral blood stem cell transplantationProcedure: autologous hematopoietic stem cell transplantationProcedure: allogeneic hematopoietic stem cell transplantationRadiation: total-body irradiationDrug: tacrolimusBiological: filgrastimDrug: etoposideDrug: cyclophosphamideDrug: cytarabineOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00039377
- Locations
- 🇺🇸
Great Falls Clinic, Great Falls, Montana, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.